<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000367411"><TermName>Bexxar regimen</TermName><TermPronunciation>(BEK-sar REH-jih-men)</TermPronunciation><TermDefinition><DefinitionText>A combination of drugs used to treat certain types of B-cell non-Hodgkin lymphoma. It is also being studied in the treatment of other types of cancer. Bexxar regimen is made up of a monoclonal antibody called tositumomab and a form of tositumomab that is linked to a radioactive substance called iodine I 131. It is a type of radioimmunoconjugate. Also called Bexxar and tositumomab and iodine I 131 tositumomab.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000711451" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Bexxar regimen&quot;" language="en" id="_3"/><MediaLink ref="CDR0000711450" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;régimen de Bexxar&quot;" language="es" id="_4"/><SpanishTermName>régimen de Bexxar</SpanishTermName><SpanishTermDefinition><DefinitionText>Combinación de medicamentos que se usa para tratar ciertos tipos de linfomas no Hodgkin de células B.  También está en estudio para el tratamiento de otros tipos de cáncer. El régimen de Bexxar está elaborado con un anticuerpo monoclonal que se llama tositumomab y una forma de tositumomab que se enlaza a una sustancia radiactiva que se llama yodo 131. Es un tipo de radioinmunoconjugado.    También se llama Bexxar y tositumomab y tositumomab con yodo 131.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2004-04-23</DateFirstPublished><DateLastModified>2011-03-03</DateLastModified><RelatedInformation><RelatedDrugSummaryRef href="CDR0000585474">Tositumomab and Iodine I 131 Tositumomab</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
